Fecha de publicación: -- Fuente: PubMed "nature biotechnology" Lancet HIV. 2026 Nov 8:S2352-3018(26)00236-5. doi: 10.1016/S2352-3018(26)00236-5. Online ahead of print.ABSTRACTHIV has generated four decades of activism, research, and policy reform that produced measurement tools, theoretical frameworks, and consensus that stigma undermines prevention, delays treatment, and entrenches inequity. Weight stigma follows a strikingly similar pattern, operating through visibility, assumptions of personal control, and moralised concern, and is now recognised as a public health priority in its own right. These two forms of stigma increasingly intersect in the same bodies: antiretroviral therapy, particularly newer regimens, is associated with substantial weight gain, so that people once stigmatised for wasting now risk a second, contradictory stigma for excess weight. This intersection is complex; internalised stigma from either condition can resurface long after apparent resolution, even when viral suppression has been reached or after major weight loss. HIV and obesity differ in diagnostic certainty, visibility, permanence, and the origins of activism and legal protection, which helps explain why HIV stigma reduction remains decades ahead. Applying the Health Stigma and Discrimination Framework to this intersection clarifies shared drivers, facilitators, manifestations, and outcomes. Community leadership, rejection of false prevention-versus-treatment trade-offs, equitable access to pharmacotherapy, and integration of obesity care into existing HIV services offer a practical path towards reducing both stigmas.PMID:43000039 | DOI:10.1016/S2352-3018(26)00236-5